strate that ICU patients worldwide are receiving nowhere near current protein recommendations (unpublished data; Daren Heyland, personal communication, 2017) . On average, patients were prescribed 94 g protein/d or approximately 1.3 g/kg/d (interquartile range, 1.0-1.5 g/kg/d; overall range, 0.5-3.8 g/ kg/d). Overall, patients from these participating ICUs received approximately 55% of prescribed protein requirements with site averages ranging from 15%-101%. When reviewing individual sites, 11 sites (5.9%) averaged providing >80% of prescribed protein amounts in all included patients, and 13 (7.3%) of the 179 sites with high nutrition risk patients as determined by the NUTrition Risk in the Critically Ill (NUTRIC, explained below) score managed to provide >80% of prescribed amounts of protein to high-risk patients. At a patient level, 634 (16.1%) patients received >80% of prescribed protein amounts, and only 296 (16.3%) high NUTRIC score patients received >80% of the prescribed amount. Note that the percentage of patients receiving 80% of prescribed protein is the same in all patients and in nutritionally high-risk patients, suggesting that practitioners are not discriminating between low-risk and high-risk patients.
Overall, protein delivery was low, with the majority of protein delivered coming from enteral nutrition (EN) formulas 691245N CPXXX10.1177/0884533617691245Nutrition in Clinical PracticeHeyland et al research-article2017 Protein Delivery in the Intensive Care Unit: Optimal or Suboptimal? (82.5%) , an additional 11.5% coming from parenteral amino acid sources, and very little coming from enteral protein supplements (5.9%) or intravenous (IV) amino acids alone without IV glucose and/or lipids (13 patients, 0.1%) (see Figure 1 ). Of note, parenteral nutrition (PN) was used in only 14.2% of included patients, enteral protein supplements were used in only 21.0% of patients, and only 7 sites used a feeding protocol that optimized the delivery of EN (ie, the Enhanced Protein-Energy Provision via the Enteral Route Feeding Protocol [PEP uP] ). Is the current practice providing adequate amounts of protein to critically ill patients?
More Is Better!
Statistical analysis of the same INS database, as well as other existing nutrition databases, revealed a relationship between increased nutrition intake (either 30 g/d more of protein and/or 1000 more calories/d) and improved clinical outcomes. For example, we have shown that for an additional 30 g protein/d or 1000 calories/d, critically ill patients have reduced infectious complications, shorter duration of mechanical ventilation, and reduced mortality. 5, 7, 8 Admittedly, the clinical inference we can make from these observational data is weak. But in the absence of stronger evidence from randomized trials, it is sufficient to inform clinical practice.
Some of the most exciting recent developments in the world of critical care nutrition include the emerging evidence that our nutrition practices may actually affect the physical recovery of critically ill patients. A recent study found that IV amino acids in ICU patients improved protein balance and stimulated an anabolic response. 9 This suggests that our nutrition strategies may be used to preserve muscle mass and muscle function, although data supporting this assertion are just accumulating. Such data include a small randomized controlled trial (RCT) demonstrating that greater protein intake is associated with improved pulmonary function in ICU patients with chronic obstructive pulmonary disease (COPD). 10 In addition, Wei and colleagues 11 conducted a long-term follow-up study of patients enrolled in a randomized trial and documented their physical function using the Short-Form 36 health status measure at 3 and 6 months. They demonstrated that for every 25% increase in nutrition intake, surviving patients had a higher physical function or better physical recovery that was statistically significant at 3 months. At 6 months, the improvements with better nutrition intake were still present and clinically important but lost statistical significance. In contrast to the prevailing data, some observational studies have reported that adverse patient outcomes were associated with higher protein intake. However, these observational studies have methodological flaws that limit the validity of their findings. Puthucheary and colleagues 12 concluded that increased protein delivery was associated with increased muscle wasting; however, when appropriate statistical modelling was applied, the association between protein intake and outcome disappeared. 5, 13 In a post hoc analysis of the Early vs Late PN trial, investigators showed an association with increased protein intake and lower likelihood of early ICU discharge.
14 However, this analysis suffers from an indication bias; sicker patients in this unblinded trial would have received more protein early on during ICU stay, and this is in turn associated with worse outcomes. 5 Moreover, the authors reported in Table 2 of the main article an early separation of groups that would have occurred day 2 and day 3, before the early PN actually started. 14 These differences were likely due to high IV glucose infusion and intensive insulin therapy and not from PN or protein intake. 15 As the data accumulate showing that nutrition interventions favorably affect the physical recovery of critically ill patients, experts have defined an evaluation framework to systematically assess the impact of nutrition interventions on muscle and muscle-related outcomes, including subsequent patient performance measures. This outcome assessment is represented in Figure 2 . This framework categorizes the outcomes of survivors of critical illness into 4 domains: (1) structure and function, (2) activity limitations within a standardized setting, (3) participation restriction in a usual environment, and (4) quality of life in a usual environment. 16 do in their usual setting (eg, home) that may or may not have environmental adaptations to aid their function at home. This approach also acknowledges that patients with similar impairments in structure and function and limitations in activities may have considerable variance in participation outcome measures in their usual setting and in quality-of-life outcomes due to various modifiers of outcomes, including differences in physical and psychological adaptations and related requirements for participation. The adoption of standardized outcomes related to functional outcomes and quality of life will facilitate the comparison of different trials evaluating the effect of protein interventions alone or in combination with other nutrition or rehabilitation-related interventions.
Is It More Calories That Matter or More Protein?
In another recent analysis using the same INS data, we demonstrated that meeting protein requirements seems to be more important than meeting caloric requirements. When we control for caloric intake, we still see a significant reduction in associated mortality when >80% of protein requirements are delivered compared with <80% (odds ratio [OR] for 60-day mortality, 0.68; 95% confidence interval [CI], 0.50-0.91). In contrast, when we control for protein administration, there is no incremental effect of increased caloric administration (OR, 0.89; 95% CI, 0.71-1.12).While the inference is weak from this statistical modeling, it is consistent with other observational studies that show an association between protein optimization and survival but a negative or absent effect of caloric intake. 18, 19 From these systematic observations, we conclude that efforts to increase protein delivery, above current practice, are warranted. Support for this assertion comes from the American Society for Parenteral and Enteral Nutrition (ASPEN)-Society of Critical Care Medicine (SCCM) 2016 Clinical Practice Guidelines that recommend the following: "sufficient (high-dose) protein should be provided. Protein requirements are expected to be in the range of 1.2-2.0 g/kg actual body weight per day and may likely be even higher in burn or multi-trauma patients." 19 Despite provocative results from these observational analyses and the intuitive nature of the hypothesis related to supporting metabolism with adequate nutrition substrates, large-scale randomized trials examining the effect of increased EN intake have not provided supportive evidence. Why might that be? First, these trials have focused on increased amounts of calories, not protein. Protein dose was either kept the same 20 or not reported, 21 but regardless, prescribed amounts were well below recommended amounts noted above. Second, not all clinically important outcomes were reported. Short-term mortality may not be the best outcome used to evaluate the effect of increased protein administration. In fact, we posit that measures of muscle mass or function or patient-based performance measures (such as the 6-minute walk test) may be more sensitive to differential amounts of protein intake. Of note, the Early vs Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (EDEN) study compared goal feeding with trophic feeding and demonstrated no difference in short-term outcomes; however, better fed patients had a trend toward improvements in long-term physical functional performance (6-minute walk test at 12 months) at 1 year. 22 A large-scale trial of supplemental PN in the context of a relative contraindication to EN also showed a significant improvement in 60-day quality of life. 23 Yet, a large-scale trial of IV amino acids infusing up to 2.0 g/kg/d in over 400 ICU patients did not result in any impact in patient-reported outcomes (mortality or quality of life). 24 How do we reconcile these conflicting observations?
Nutrition Risk Assessment in the Critically Ill
We propose that the conflict between observational and interventional studies can, in part, be resolved using our nascent understanding of nutrition risk assessment in the critically ill. Large-scale RCTs may have failed to demonstrate an impact of different amounts of nutrition intake because they enroll heterogeneous patient populations of varying nutrition risk, not all of whom will respond to optimal nutrition intake. We posit that not all critically ill patients are the same in terms of their nutrition risk. The evidence for this assertion comes from studies that demonstrate a differential treatment effect of artificial nutrition in different subgroups of ICU patients. [24] [25] [26] So how do we begin to approach determining "nutrition risk" in the critical care setting? Conceptually, nutrition status in ICU patients will be a function of both undernourishment and inflammation, both of which occur in the acute and chronic setting. Using this conceptual model, we developed and validated the NUTRIC score, which was designed to identify critically ill patients who would have the greatest benefit from optimizing nutrition intake. 27 The NUTRIC score considers the patient's age, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, Sequential Organ Failure Assessment (SOFA) score, number of comorbidities, time in hospital prior to ICU admission, and interleukin-6 (IL-6) levels in developing an understanding of which patients will benefit the most from artificial nutrition therapy (see Table 2 ). The NUTRIC score is also now validated without the IL-6 level. 28 In 3 distinct analyses from 3 separate databases, we have shown that patients with high NUTRIC scores are less likely to die if they received closer-to-goal calories or protein compared with low NUTRIC score patients when there is no relationship between nutrition intake and outcome. [27] [28] [29] In addition, the NUTRIC score has been validated by independent investigators in Asian, Brazilian, and Portuguese populations. [30] [31] [32] In contrast, Arabi and colleagues 33 recently published a post hoc analysis of the Permissive Underfeeding versus Target Enteral Feeding in Critically Ill Adults (PERMIT) trial, where patients were randomized to different levels of caloric intake, and they analyzed the effect with high vs low NUTRIC groups of patients. Consistent with the overall results of the PERMIT trial, 34 they did not demonstrate any differential effect of caloric intake in high vs low NUTRIC patients. While the analysis was grossly underpowered (as evidenced by very wide CIs around point estimates), we point out that protein intake was the same in all patient groups, and as noted above, protein intake is probably more important than caloric intake. While definitive proof from prospective RCTs evaluating different levels of protein intake in nutritionally high-risk patients is lacking, based on the strength of evidence from the aforementioned observational studies, efforts to improve protein intake, especially in high nutrition risk critically ill patients, are warranted.
How to Increase Protein Delivery in ICU Patients?
In modern ICU medicine, the main cause of protein underdelivery in the ICU is related to the frequent interruptions to enteral feeding because of impending or current procedures. 35 To maximize EN delivery, we first need to minimize the time patients are nil per os with protocols that minimize these interruptions. 36 Then, using existing products and strategies, there are several methods by which practitioners can increase protein/amino administration in the ICU setting: using a high-protein enteral formula, adding protein supplements to the existing EN order, implementing novel enteral feeding protocols that include protein delivery enhancement strategies and/or volume-based feeding strategies, 35, [37] [38] [39] [40] and supplementation with parenteral amino acids alone or PN. 41 Recently, commercially available high-protein enteral solutions have become available (35%-37% protein, 88-92 g/L), 42, 43 and there is emerging evidence that these products may translate into greater protein intake compared with usual care practices cited above. 44, 45 Although protein supplements are readily available in most practice settings, they are infrequently used and, as noted earlier, contribute very little to overall protein intake in most patients.
We have recently bundled the use of a specialty formula with protein supplements and other strategies to enhance the delivery of protein to critically ill patients in the form of a novel feeding protocol, the PEP uP. Combined with a nursing educational intervention, we have shown that this feeding protocol is superior compared with a standard feeding protocol (usual care) on amount of protein and calories received by study patients. 35, 46, 47 An integral part of PEP uP is the concept of volume-based feeding prescriptions where patients are prescribed the targeted amount expressed as a 24-hour volume goal. Compared with traditional hourly based targets, volumebased protocols have been shown to deliver significantly more protein and calories in several before-after studies of ICU patients. [38] [39] [40] Typically, the amount of protein supplement to prescribe is determined as the difference between what would be administered as part of the enteral formula, once the goal rate has been reached, and the protein target. Given that patients are underfed almost uniformly during the first week, protein deficits will still occur with this approach. An alternative approach is to deliver the entire protein requirement as supplement while the enteral feeding is being increased to the target rate (see Figure 3 for example of such a protocol). The supplement can be safely administered as a small volume bolus (typically 150 mL or less) 3-4 times daily. To avoid administering over the target amount of protein, the supplemental amount can be reduced once the patient is receiving over a predetermined volume of enteral feeding (eg, 50%-75% of target for 24 hours). In a small, singlecenter trial, O'Keefe and colleagues (unpublished data; Grant O'Keefe, personal communication, 2017) demonstrated the efficacy of such an approach (see Figure 4) . Admittedly, there is limited information evaluating the disposition and utilization of these protein supplements and whether one type is better than another. But in the absence of better information, practitioners are encouraged to use this strategy for increasing overall protein intake given the evidence reviewed above.
Parenteral sources of protein/amino acids are also readily available. IV amino acids of up to 2.0-2.5 g/kg/d have been shown to be feasible and safe. 24 However, there is little evidence that these practices are used commonly around the world. More commonly is the use of supplemental PN as a means of providing both supplemental energy and protein. Past trials have primarily focused on this strategy as increasing the delivery of calories but not necessarily protein. 23, 48, 49 Most of the currently available PN products contain suboptimal concentrations of amino acids. Large volumes required to provide adequate protein/amino acid intake are often not tolerated. Newer products with higher amino acid concentrations are needed. Heyland and colleagues recently completed a multicenter trial of supplemental PN using a high nitrogen-containing solution (OLIMEL N9, containing 9 g nitrogen/L and final concentration of amino acids is 5.7%; Baxter, Deerfield, IL) and achieved good success with protein delivery. Patients in the intervention group received 86% of their prescribed protein intake compared with 64% in the control group (EN alone) (unpublished data; Daren Heyland, personal communication, 2017). As all these practices are currently underused, there exists a tremendous opportunity to improve current practice by rapid and efficient dissemination and implementation of these nutrition strategies and products.
How to Monitor Protein Administration?
How do we know when enough is enough for an individual patient? Perhaps there is something in the blood that we can measure that will indicate when a patient has received sufficient protein/amino acid administration? Traditional serum protein markers (serum albumin, prealbumin, transferrin, retinol-binding protein) are not markers of nutrition status in critical illness and are not recommended. 19 However, in addition to providing a strong scientific rationale for the potential efficacy of protein therapy, emerging basic and translational science studies suggest that other amino acid-sensitive markers in the blood may be helpful in this context. As key regulators of protein balance, intracellular amino acid-sensing Guideline for Administering Supplemental Protein 1. Supplemental protein will be administered to deliver ~1.5 g/kg of protein/day (1.2-1.5 g/kg in the medical patient and 1.5-2 g/kg in burn, surgical, and trauma patient after the patient is deemed ready to start enteral feeding.
2. Protein supplementation will be administered as a bolus via the nasal/oral feeding tube, 2-4 times per day depending on product used.
3. Enteral feeding will be ordered according to current institutional protocols but supplemental protein will be calculated and administered independently of recommended formula intake. 4 . Supplemental protein will be reduced by 50% if a patient received 75% of caloric intake over the previous 24-hour period.
5. Once the patient reaches target caloric intake for 48 hours, supplemental protein will be calculated to include the protein contained in the enteral formula and adjusted accordingly.
6. Consider 24-hour urine collections weekly in order to determine nitrogen balance and to guide adjustments in protein supplementation. proteins are activators of anabolic processes that promote cell growth and survival, and these same cell signaling mechanisms might promote positive protein balance, limit inflammation and organ injury, improve immune function, and attenuate muscle atrophy. [50] [51] [52] [53] [54] [55] All cells respond to low levels of amino acids via 2 highly conserved biochemical-sensing mechanisms that are mediated by the protein kinases; mammalian target of rapamycin (mTOR) and general control nonderepressible-2 (GCN2) in the endoplasmic reticulum (ER) stress response. 56, 57 Via these pathways, amino acid depletion leads to inhibition of energy-consuming processes (eg, protein synthesis, mitochondrial biogenesis) and induction of compensatory energy-recycling responses (eg, autophagy, use of alternative energy sources). Prolonged or excessive inactivation of mTOR or ER stress can promote inflammation and programmed cell death in cultured cells. 57 In agreement, pharmacological blockade of mTOR can enhance inflammation, cell death, and organ injury in animal models. 58 Both mTOR and GCN2 regulate distinct gene, protein, and cell behavior responses that can reflect amino acid availability and might be readily measured in the clinical setting to identify patients who respond to protein therapy. More work in this area is needed.
Other possibilities to monitor the effect of nutrition intervention on protein degradation include the use of the cleaved fraction of α-actin. Caspase-3 is a protease that facilitates the destruction of intact muscle fibers to release monomeric contractile proteins such as actin and myosin for degradation by the ubiquitin-proteasome system into amino acids. 59 During the cleavage of muscle proteins, caspase-3 leaves behind a characteristic 14-kD actin fragment in the insoluble fraction of muscle, and characterization of this fragment identifies the presence of muscle catabolism. 60 Some investigators have reported the use of the cleaved fraction of α-actin (14 kDa) as a tool to assess muscle protein degradation in humans. 60 Another tool used to reflect change in total body protein stores is determination of nitrogen balance. Simply put, this is the difference between nitrogen intake and loss. The majority of nitrogen excretion occurs via the kidneys. Urinary nitrogen excretion typically increases during critical illness, and measuring 24-hour urinary nitrogen, either as urea nitrogen (UUN) or total urinary nitrogen (TUN), has been used to determine protein needs. Each has its limitations; UUN seems to underestimate total nitrogen excretion (particularly in the most catabolic patients), and TUN is not widely available. Nevertheless, measuring urinary nitrogen can help us estimate an individual patient's catabolic state and perhaps guide protein administration. The presently recommended range of protein intake is broad, and measurement of urine nitrogen excretion could help us be more precise in our protein prescriptions. However, this measure only provides information on the net result of nitrogen exchange, providing no insight on protein dynamics, including synthesis, degradation, or redistribution during times of stress. In addition, a "steady state" of intake and loss is needed for measurement, which is highly unlikely in the critically ill patient due to interruptions of nutrition, presence of infection and inflammation, use of sedation and analgesics, and different clinical conditions (eg, cancer, acute renal or liver failure). 61 Still, this is a low-cost technique that can be done in any ICU, and provided that measurement errors or inaccuracies in specimen collection are avoided, the test results may offer insights into the adequacy of protein intake. Dickerson et al 62 demonstrated in a large cohort of trauma patients that the daily protein intake increased to 1.5-20 g/kg/d, the nitrogen balance studies becomes less negative and even some resulted in a positive balance (as if to confirm that more protein is better).
Is there an opportunity to use personalized medicine to guide nutrition support and protein supplementation in critically ill patients? Genomics, proteomics, and metabolomics provide the tools for systemwide interrogation of biological systems and ultimately will guide personalized medicine. Metabolomics is the high-throughput study of small molecules like amino acids, nitrates, sugars, and lipids and may be ideally suited to guiding protein supplementation. 63 Using targeted metabolomics, we have observed changes in pathways related to protein, carbohydrate, and nucleic acid synthetic pathways and in pathways related to oxidative stress in the first week after traumatic injury. 64 It may be possible to use these measures to track a patient's response to nutrition support. Traditionally, we have used individual biomarkers, but metabolomics is a systemwide and simultaneous assessment of the substrate/product balance in multiple metabolic pathways. Mass spectrometry (MS) or nuclear magnetic resonance (NMR) metabolomics analyses of biological fluids can precisely quantify metabolic states in individuals to better characterize disease and to better understand response to treatment. In our work referenced above, 63 targeted metabolomics demonstrated that circulating concentrations of amino acids and urea cycle intermediaries were reduced after traumatic injury and gradually returned toward levels seen in healthy, uninjured individuals over the first week after injury. In a second cohort of trauma victims, we observed changes in circulating concentrations of amino acids and urea cycle intermediaries within days, specifically in response to starting EN. 65 For example, within 3 days, tryptophan and citrulline increased toward levels observed in healthy control subjects (these changes did not occur in response to PN). In contrast to protein biomarkers, amino acids and related metabolites can provide a more rapid picture of metabolic state and substrate needs.
At the same time that clinically useful biomarkers are being developed for measures of nutrition status, direct measures of muscle volume and mass may also be useful in monitoring nutrition adequacy. Traditional reference standards for muscle imaging, such as computed tomography (CT), magnetic resonance imaging, or dual energy x-ray absorptiometry (DEXA), are not practical for critically ill patients. Recently, ultrasonography, an accessible, noninvasive, portable, and user-friendly tool, has been gaining popularity in the ICU and can be used to quantify structural and physical characteristics of skeletal muscle at the bedside. Diverse ultrasound (US) protocols have been developed and applied in an ICU setting to quantify muscle thickness or track its changes over the ICU trajectory and relate these measures to clinical and functional outcomes. 12, [66] [67] [68] However, most of these protocols have been validated only in healthy populations and then subsequently applied to critically ill populations. Our group recently conducted the first study to validate the US measure of the thickness of the quadriceps and demonstrated that the measurement, in the hands of non-ultrasonographers, has good reliability but only modestly correlates with the reference standard of the CT scan of third lumbar vertebrae estimates of lean muscle mass. 69 Chapple and colleagues 70 have furthered the utility of US of quadriceps thickness, showing that it strongly correlates with DEXA and subsequent 3-month health-related quality-of-life measures, the latter observation demonstrating an important relationship between measures of muscle mass and subsequent functional recovery in ICU survivors. Instead of a reference standard, repeated bedside US measurements using a protocol with high intrareliability and interreliability could potentially be used to demonstrate an individual patient's rate of loss/gain of muscle mass. Further work needs to be done to optimize the measurement technique, and perhaps, in combination with other readily available clinical measures, this US measurement can be used to identify patients with low muscularity and monitor success with protein administration over time in surviving critically ill patients.
Maximizing the Effect of Protein Administration
With increasing recognition of the burden of survivorship and the associated physical impairments, there has been an increasing interest in early ICU-based exercise/rehabilitation strategies. These interventions have shown reductions in durations of mechanical ventilation and ICU stay as well as improved physical function. 71 However, existing studies have not reported nutrition intake or have grossly underfed their patients. [72] [73] [74] [75] Hence, there may be an opportunity to further improve the outcomes of the critically ill by combining nutrition optimization strategies with early ICU rehabilitation and exercise practices. 16 Studies in a variety of non-critically ill populations with conditions that produce muscle atrophy showed that combining protein and exercise interventions has the largest treatment effects compared with either nutrition or exercise alone. For instance, in older people, combined exercise and protein supplements improve protein synthesis and strength vs either intervention alone. [76] [77] [78] [79] [80] In 1 study, combined exercise and protein in elders increased strength by 40% over exercise alone and by 130% over supplementation alone. 80 In patients with obesity, 81 human immunodeficiency virus/ AIDs, 82 and COPD, 83 as well as healthy volunteers undergoing bedrest, 84, 85 combined exercise and nutrition (vs nutrition alone) yields the greatest benefit on muscle mass and strength.
In a meta-analysis, protein supplementation and exercise (vs exercise alone) enhanced strength and muscle mass in noncritically ill adults. 86 Moreover, a recent RCT of 93 ICU survivors, conducted in the outpatient setting, demonstrated that combined oral amino acid supplements and exercise improved 6-minute walk distance (the primary outcome for our proposed RCT) measured 3 months after enrollment compared with either intervention alone. 87 Although these findings may not be generalizable to patients early in critical illness, the data provide biologic plausibility and scientific premise for future studies addressing this combined intervention for the reduction of physical impairments.
Conclusions
Admittedly, controversy exists regarding optimal protein and amino acid doses in critically ill patients. However, based on the data and scientific arguments reviewed herein, it is clear that current nutrition practices are providing suboptimal amounts of protein/amino acids to critically ill patients. While it is difficult to be precise about how much protein critically ill patients require (and likely that amount varies across patient groups and within a patient over time), it is likely that "more" rather than "what" is currently, and suboptimally, being administered will result in improved outcomes for this patient population, especially for nutritionally "high-risk" patients. We encourage practitioners to achieve a minimum of 1.2-1.5 g/ kg/d and a maximum that approximates 2.0-2.5 g/kg/d. Fortunately, several existing clinical strategies (PEP uP, volume-based feeds) and commercially available products (highprotein enteral solutions, protein supplements, and parenteral amino acid-containing solutions) are readily available and ready for implementation. We recommend practitioners audit their own practice to determine the level of protein intake of their patients and, if inadequate, consider using some of these products and strategies to increase protein intake. In addition, clinically available surrogate markers of nutrition success are being developed and will greatly facilitate the design, interpretation, and comparison of clinical trials of protein delivery and/ or exercise in the critically ill. While future research clarifies the exact amount of protein required in various case mix groups of ICU patients or strengthens the available evidence that "more is better," current quality improvement initiatives should work toward improving current practice, so current patients receive more protein. This is based on the notion that by waiting for confirmatory evidence or more precise information, current patients are possibly being harmed. Further research should also develop better tools to enable bedside practitioners to monitor optimal or adequate protein intake for individual patients. Finally, exploring the effect of combining protein intake with early mobility/exercise in the ICU setting has the greatest potential for improving the outcomes of survivors of critical illness and warrants further study.
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Peter J. M. Weijs: I cannot prove that when you give more protein on the second or the third day, it would actually make the basis for an outcome benefit. There is something important about the first days of ICU stay, because you accumulate calorie or protein deficits. Can you be more specific about how much you give and what the time period is that you cover? Because that may also affect the relationship with outcome.
Daren K. Heyland: These data come from the International Nutrition Survey, where all participants collect the first 12 days of nutrition intake. So the numbers that I create are cumulative over the first 12 days. If you're in that group that doesn't get 80%, it's because in that early phase of critical illness, you are not getting anything or you aren't getting much. That's where the debt comes from, that you just never catch up. Those people who get up to 80 quickly and stay there for the first 12 days are the ones where we're seeing all the benefit. Peter J. M. Weijs: To be specific, does that mean 1 g/kg/d as a mean value over 10 days? Daren K. Heyland: We are not influencing what people are doing. They're setting a prescription on average of 1.2-1.3 g/ kg/d, and they're getting 80% of that expressed over the 12-day period. In the Wei paper that I presented where we looked at outcome and SF-36 scores, we actually just looked at the nutrition over the first 7 or 8 days because it was based on the EPaNIC analysis.
Jorge A. Coss-Bu: When your data indicate that 80% is the cutoff for statistically significant benefit, is that after you do all the adjustments? At what cutoff do you think you would start seeing some potential clinical benefit? How easy is it to get the 80%? What percentage of your data or what percentage of the patients actually reaches 80%? For those patients who have a high NUTRIC score, does differentiating the malnourished from the not so malnourished (all of whom have a high risk of mortality) identify those patients who will have improved outcome by providing better nutrition? And finally, can you comment on all the controversies and discussion with supplemental PN, because the pediatric data from the EPaNIC study were published this year as well and have generated many comments in the pediatric ICU community.
Daren K. Heyland:
In the one paper I showed you, we actually started looking at quintiles, grouping patients by 20% increments. The observed odds ratio was the same until we hit that knuckle at 80%. Thus, we can't show that there's a treatment effect until you hit that 80% mark. With respect to NUTRIC, I think this is an important conversation, because if you look carefully, there aren't the traditional malnutrition risk factors included in NUTRIC. They fell out because of so much missing data that in any statistical gyration, you'll never see a significant relationship with anything. In my own mind, I use NUTRIC as a way or restratifying high vs low, but if they've got a history of weight loss, a history of reduced oral intake, I further stratify. So, for example, you might have someone who has a high NUTRIC score and is positive for malnutrition risk factors-those are really, really high-risk patients. But even the low NUTRIC patients, if they've got malnutrition risk factors, I would treat them at a moderate level of aggressivity.
Beth Taylor: Not only do I look at NUTRIC, but I also look at the severe acute protein malnutrition. We have a board outside of each of our patient rooms. If they're high risk, they get a little red high-risk dot. The nurses know that they better be feeding them while I'm on duty, because those are the ones who are going to benefit the most. You've got to help the rest of the team focus on where the efforts really need to go. They don't have to worry about the prescription, I'll worry about that part. But then they can help get the delivery done. The only other comment I was going to say is that when we can't use enteral and we use parenteral, sometimes that's challenging because of the volume that it takes to get protein in. We use a 10% solution, but sometimes even that is challenging. Going back to enteral in surgery, they won't let me feed adequately by day 3 of 4. How am I going to get to goal? What about those patients? Would you give them IV amino acids for those first 4 days? What is the importance of protein in that first 48 hours following surgery? Daren K. Heyland: I'm not sure in the first 48 hours. We are using IV amino acids in our Nexis study. At 96 hours, we start both the exercise and the intravenous infusion of amino acids. Robert G. Martindale: Is there ever an indication to give just amino acids without any other nutrient background, not knowing what they're getting? I don't think we should give amino acids without some energy background.
The plan to provide intravenous amino acids is in the context of standard enteral feeding, which we know is going to underdeliver both energy and protein. I wanted to underscore what Beth said in terms of the NUTRIC score and its utilization. My concern is that we have designed and interpreted our large-scale clinical trials ignorant of nutrition risk. So if you just read the abstract, it seems to show that it doesn't matter how you feed people. And that is what most nonnutritionally minded intensives do. They're forgetting that these patients with high NUTRIC scores, their very malnourished patients, are being harmed because they're treating everybody the same with trophic feeding. So, I love that you've got these red flags, this is a high-risk patient, and everybody needs to pay attention.
Roland N. Dickerson: For clinicians. I'm going to say something controversial and then I'm going to put a caveat to that. My controversial statement is, please stop doing large level I randomized controlled trials. The reason I'm saying that is we can't give what we want to give. We're putting the cart before
